USANA Health Sciences, Inc. (NYSE:USNA) Holdings Lowered by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 5.4% in the fourth quarter, HoldingsChannel reports. The firm owned 84,254 shares of the company’s stock after selling 4,816 shares during the period. Bank of New York Mellon Corp’s holdings in USANA Health Sciences were worth $3,024,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Barclays PLC lifted its holdings in shares of USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after purchasing an additional 14,647 shares in the last quarter. Rhumbline Advisers raised its position in USANA Health Sciences by 39.8% during the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after buying an additional 14,068 shares during the period. Principal Financial Group Inc. lifted its stake in USANA Health Sciences by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock worth $1,924,000 after acquiring an additional 1,480 shares in the last quarter. Geode Capital Management LLC boosted its position in USANA Health Sciences by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock worth $11,269,000 after acquiring an additional 12,898 shares during the period. Finally, State Street Corp grew its stake in USANA Health Sciences by 0.6% during the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after acquiring an additional 2,782 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Price Performance

Shares of USNA stock opened at $27.24 on Friday. USANA Health Sciences, Inc. has a fifty-two week low of $26.78 and a fifty-two week high of $49.78. The stock’s 50-day moving average is $31.94 and its two-hundred day moving average is $35.57. The firm has a market cap of $514.92 million, a P/E ratio of 9.62, a PEG ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, research analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on USNA shares. DA Davidson reduced their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,234 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now owns 12,775 shares of the company’s stock, valued at $421,319.50. This represents a 20.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. This represents a 24.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock worth $500,285 in the last 90 days. 0.33% of the stock is owned by insiders.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.